热门资讯> 正文
EyeGate Pharma rallies 67% on development path for conjunctivitis treatment
2020-08-12 19:05
Thinly traded nano cap EyeGate Pharmaceuticals(NASDAQ:EYEG)jumps67%premarket on light volume in reaction to its announcement that the FDA has clarified a development path for MoxiGel, a combination of its Ocular Bandage Gel and an antibiotic, for the potential treatment of bacterial conjunctivitis.
An IND is on tap for H1 2021.
Ocular Bandage Gel, based on a modified form of the natural polymer hyaluronic acid, is designed to stay on the corneal surface longer.
See all stocks on the move »
Now read:FDA gives green signal to IGC's cannabinoid early-stage trial in Alzheimer’s disease »
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
